Evidence map›Paper›PMID 34296479›Full record

ArticleCell proliferation2021

The different biological effects of TMPyP4 and cisplatin in the inflammatory microenvironment of osteosarcoma are attributed to G-quadruplex.

Jianqiang Chen, Xiangxiang Jin, Yanan Mei, Zhe Shen, Jufan Zhu, Hongyi Shi, Minshan Wang, Xiaohui Zheng, Guang Liang

Open access · goldAbstract read
In one paragraph

Article in Cell proliferation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Telomeres and telomerase in Sarcoma disease and therapy.International journal of medical sciences · 2024
    Review
  4. Review
  5. Article
  6. Article
  7. Crosstalk between G-quadruplex and ROS.Cell death & disease · 2023
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jianqiang ChenChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Xiangxiang JinChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Yanan MeiChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Zhe ShenChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Jufan ZhuChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Hongyi ShiChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Minshan WangThe Affiliated Xiangshan Hospital, Wenzhou Medical University, Ningbo, China.
Xiaohui ZhengChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.
Guang LiangChemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China.ORCID https://orcid.org/0000-0002-8278-849X
Wenzhou Medical University · CN

Funding

National Natural Science Foundation of China 21701194National Natural Science Foundation of China 81930108Research Grant from Health Commission of Zhejiang Province 2019KY646Wenzhou Basic Medical and Health Technology Project Y20180177Wenzhou Science and Technology Key Project 2018ZY009Zhejiang Provincial Key Scientific Project 2018C03068Zhejiang Provincial Key Scientific Project 2021C03041
6 · The paper itself

Abstract

objectiveOsteosarcoma (OS) is characterized by high levels of the tumour-associated inflammatory microenvironment. Moreover, in approximately 60% of OS, telomere length is maintained by alternative lengthening of telomeres (ALT) pathway. Whether the ALT pathway can be exploited for OS therapeutic treatment and how the OS inflammatory microenvironment influences the anti-cancer drug effect remains unknown. Here, we examined the biological effects of TMPyP4 and cisplatin in the inflammatory microenvironment of OS cells. MATERIALS AND

methodsImmunofluorescence in situ hybridization (IF-FISH) and C-circle experiments were used to detect the G-quadruplex and ALT activity. The redox potential of single guanine, G-quadruplex and G-quadruplex/TMPyP4 was evaluated by the lowest unoccupied molecular orbital energy (LUMO), zeta potential and cyclic voltammetry. Cell viability, flow cytometry and apoptosis, Western blot, comet assay, adhesion, transwell and scratch experiments were performed to compare the anti-tumour proliferation and migration effects of TMPyP4 and cisplatin in the inflammatory microenvironment.

resultsThis study indicated that compared with cisplatin, TMPyP4 could induce the formation of human telomeres and FAK G-quadruplex in vitro and in vivo, and TMPyP4-treated OS cells showed fewer extrachromosomal C-circles and fewer ALT-associated promyelocytic leukaemia bodies. Consequently, the ALT activity and FAK-related cell migration were suppressed by TMPyP4. Mechanistically, the formation of G-quadruplex resulted in both lower redox potential than G within the genome and FAK transcription inhibition, and TMPyP4 could enhance this phenomenon, especially in the inflammatory microenvironment.

conclusionsOur results reveal that TMPyP4 is more suitable for OS treatment than cisplatin.

Indexed as

Antineoplastic AgentsApoptosisCell Line, TumorCell MovementCell SurvivalCisplatinG-QuadruplexesHumansOsteosarcomaPorphyrinsTelomeraseTelomereTumor MicroenvironmentAntineoplastic AgentsCisplatinPorphyrinsTelomerasetetra(4-N-methylpyridyl)porphinecisplatinG-quadruplexinflammatory microenvironmentosteosarcomaTMPyP4

Identifiers

PMID34296479
PMCPMC8450119
OpenAlexW3185943571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.